Medical condition
Non Small Cell Lung Cancer
Non Small Cell Lung Cancer is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- bevacizumab (ABEVMY) Antineoplastic and immunomodulating agents (L01)
- crizotinib (XALKORI) Antineoplastic and immunomodulating agents (L01)
- dacomitinib (VIZIMPRO) Antineoplastic and immunomodulating agents (L01)
- entrectinib (ROZLYTREK) Antineoplastic and immunomodulating agents (L01)
- durvalumab (IMFINZI) Antineoplastic and immunomodulating agents (L01)
- gefitinib (CIPLA GEFITINIB) Antineoplastic and immunomodulating agents (L01)
- atezolizumab (TECENTRIQ) Antineoplastic and immunomodulating agents (L01)
- ceritinib (ZYKADIA) Antineoplastic and immunomodulating agents (L01)
- selpercatinib (RETEVMO) Antineoplastic and immunomodulating agents (L01)
- alectinib (ALECENSA) Antineoplastic and immunomodulating agents (L01)
- sugemalimab (CEJEMLY) Antineoplastic and immunomodulating agents (L01)
- amivantamab (RYBREVANT) Antineoplastic and immunomodulating agents (L01)
Clinical pipeline & programs
Explore Oncology drug development programs tracked across clinical phases.